Company news

Fortress Biotech, Inc. news in 2026

Fortress Biotech, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

November 10, 2026

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 13, 2026

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing

July 28, 2026

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing

July 27, 2026

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

May 18, 2026

Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 14, 2026

Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

May 4, 2026

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

March 30, 2026

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

March 29, 2026

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

March 17, 2026

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

February 22, 2026

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

February 22, 2026

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

February 22, 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO, the First and Only Approved Treatment for Menkes Disease in the United States

January 14, 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

January 13, 2026

Decks in 2026